Publications

2022

Harris AE, Metzler VM, Lothion-Roy J, Varun D, Woodcock CL, Haigh DB, et al. Exploring anti-androgen therapies in hormone dependent prostate cancer and new therapeutic routes for castration resistant prostate cancer. Front Endocrinol (Lausanne). 2022;13:1006101.
Groha S, Alaiwi SA, Xu W, Naranbhai V, Nassar AH, Bakouny Z, et al. Germline variants associated with toxicity to immune checkpoint blockade. Nat Med. 2022;28(12):2584-2591.
Fontugne J, Cai PY, Alnajar H, Bhinder B, Park K, Ye H, et al. Collision tumors revealed by prospectively assessing subtype-defining molecular alterations in 904 individual prostate cancer foci. JCI Insight. 2022;7(4).
Vougiouklakis T, Zhu K, Vasudevaraja V, Serrano J, Shen G, Linn RL, et al. Integrated Analysis of Ovarian Juvenile Granulosa Cell Tumors Reveals Distinct Epigenetic Signatures and Recurrent TERT Rearrangements. Clin Cancer Res. 2022;28(8):1724-1733.
Han J, Russo G, Stratman S, Psomadakis CE, Rigo R, Owji S, et al. Toxic epidermal necrolysis-like linear IgA bullous dermatosis after third Moderna COVID-19 vaccine in the setting of oral terbinafine. JAAD Case Rep. 2022;24:101-104.
Nascimento J, Mariot C, Vianna DR, Kliemann LM, Chaves PS, Loda M, et al. Fatty acid synthase as a potential new therapeutic target for cervical cancer. An Acad Bras Cienc. 2022;94(2):e20210670.
Lin M, Ku AT, Dong J, Yue F, Jiang W, Ibrahim AA, et al. STAT5 confers lactogenic properties in breast tumorigenesis and restricts metastatic potential. Oncogene. 2022;41(48):5214-5222.
Butler-Laporte G, Gonzalez-Kozlova E, Su C-, Zhou S, Nakanishi T, Brunet-Ratnasingham E, et al. The dynamic changes and sex differences of 147 immune-related proteins during acute COVID-19 in 580 individuals. Clin Proteomics. 2022;19(1):34.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700